Efficacy of trivalent inactivated influenza vaccines in the cotton rat Sigmodon hispidus model

Vaccine

Volumn 30, Issue 7, 2012, Pages 1291-1296

  Yim, Kevin ^a,b   Miles, Brian ^b   Zinsou, Rachel ^b   Prince, Gregory ^b   Boukhvalova, Marina ^a,b  

^a Sigmovir Biosystems Inc   (United States)

^b Virion Systems Inc   (United States)

Author keywords

Animal model; Influenza vaccines; TIV

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COTTON RAT; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; EXPERIMENTAL ANIMAL; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LUNG; NONHUMAN; PRIORITY JOURNAL; RAT; SIGMODON HISPIDUS; UPPER RESPIRATORY TRACT; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LUNG; NOSE; ORTHOMYXOVIRIDAE INFECTIONS; SIGMODONTINAE; VACCINATION; VACCINES, INACTIVATED; VIRAL LOAD; VIRUS REPLICATION;

EID: 84856581620     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.084     Document Type: Article

References (22)

1. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(16):1776-1779.
2. Jefferson T., Di Pietrantonj C., Rivetti A., Bawazeer G.A., Al-Ansary L.A., Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010, 7. CD001269.
3. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000, 284(13):1655-1663.
4. Ritzwoller D.P., Bridges C.B., Shetterly S., Yamasaki K., Kolczak M., France E.K. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age: with 1 vs 2 doses. Pediatrics 2005, 116(1):153-159.
5. Bouvier N.M., Lowen A.C. Animal models for influenza virus pathogenesis and transmission. Viruses 2010, 2(8):1530-1563.
6. Ottolini M.G., Blanco J.C., Eichelberger M.C., Porter D.D., Pletneva L., Richardson J.Y., et al. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 2005, 86(Pt 10):2823-2830.
7. Baccam P., Beauchemin C., Macken C.A., Hayden F.G., Perelson A.S. Kinetics of influenza A virus infection in humans. J Virol 2006, 80(15):7590-7599.
8. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(1):1-15.
9. Ottolini M., Blanco J., Porter D., Peterson L., Curtis S., Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 2003, 36(4):290-294.
10. Neuzil K.M., Dupont W.D., Wright P.F., Edwards K.M. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001, 20(8):733-740.
11. Herrera G.A., Iwane M.K., Cortese M., Brown C., Gershman K., Shupe A., et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine 2007, 25(1):154-160.
12. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120(5):1663-1673.
13. Ding H., Tsai C., Zhou F., Buchy P., Deubel V., Zhou P. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. PLoS One 2011, 6(3):e17821.
14. Gioia C., Agrati C., Castilletti C., Capobianchi M.R., Martini F. Influenza pandemics, immune cross-reactivity, and pandemic control strategies. J Infect Dis 2008, 198(2):294-295. author reply 295-296.
15. Straight T.M., Ottolini M.G., Prince G.A., Eichelberger M.C. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol J 2008, 5:44.
16. Straight T.M., Ottolini M.G., Prince G.A., Eichelberger M.C. Evidence of a cross-protective immune response to influenza A in the cotton rat model. Vaccine 2006, 24(37-39):6264-6271.
17. Kuiken T., Taubenberger J.K. Pathology of human influenza revisited. Vaccine 2008, 26(Suppl. 4):D59-D66.
18. Buynak E.B., Weibel R.E., McLean A.A., Hilleman M.R. Live respiratory syncytial virus vaccine administered parenterally. Proc Soc Exp Biol Med 1978, 157(4):636-642.
19. Prince G.A., Potash L., Horswood R.L., Camargo E., Suffin S.C., Johnson R.A., et al. Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun 1979, 23(3):723-728.
20. Harris K., Ream R., Gao J., Eichelberger M.C. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol J 2011, 8:251.
21. Powers D.C., Fries L.F., Murphy B.R., Thumar B., Clements M.L. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991, 29(3):498-505.
22. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008, 26(Suppl 4):D31-D34.